SCHEMBL17153248

SCHEMBL17153248

O=CNc1cccc(C2OCCO2)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.43
HTT P42858 3/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
LMNA P02545 1/20 0.43
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
ATM Q13315 1/20 0.38
BUB1 O43683 1/20 0.36
MEN1 O00255 2/20 0.31
KMT2A Q03164 2/20 0.31
CYP2C19 P33261 1/20 0.31
CASP7 P55210 1/20 0.30
MAPT P10636 1/20 0.30
MAPK1 P28482 1/20 0.30
CCNB2 O95067 1/20 0.30
CDK1 P06493 1/20 0.30
CCNB1 P14635 1/20 0.30
GSK3B P49841 1/20 0.30
CDK5 Q00535 1/20 0.30
CDK5R1 Q15078 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12398867 0.83 SMN1; SMN2 (0.39) ALDH1A1HTTSMN1; SMN2LMNANPC1
SCHEMBL12401737 0.80 SMN1; SMN2 (0.41) ALDH1A1HTTSMN1; SMN2LMNANPC1
SCHEMBL3836474 0.79 NPC1 (0.41) ALDH1A1HTTSMN1; SMN2LMNANPC1
SCHEMBL31195400 0.79 ALDH1A1 (0.43) ALDH1A1SMN1; SMN2LMNANPC1RAB9A
SCHEMBL28193519 0.77 ALDH1A1 (0.47) ALDH1A1NPC1
SCHEMBL17010980 0.75 ALDH1A1 (0.41) ALDH1A1HTTSMN1; SMN2LMNANPC1
SCHEMBL9262464 0.75 ALDH1A1 (0.39) ALDH1A1HTTSMN1; SMN2LMNAMEN1
SCHEMBL25769846 0.74 PRKCI (0.42) ALDH1A1NPC1
SCHEMBL5362260 0.74 ALDH1A1 (0.51) ALDH1A1HTTSMN1; SMN2NPC1RAB9A
SCHEMBL2281435 0.74 ALDH1A1 (0.42) ALDH1A1HTTSMN1; SMN2LMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10017509-B2 Macrocylic pyrimidine derivatives JANSSEN PHARMACEUTICA NV (BE) 2018-07-10 US disclosed
US-10017509-B2 Macrocylic pyrimidine derivatives JANSSEN PHARMACEUTICA NV (BE) 2018-07-10 US disclosed
EP-3126364-B1 MACROCYLIC PYRIMIDINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2018-02-07 EP disclosed
US-20170022202-A1 MACROCYLIC PYRIMIDINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2017-01-26 US disclosed
WO-2015150555-A1 MACROCYLIC PYRIMIDINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2015-10-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170022202-A1 MACROCYLIC PYRIMIDINE DERIVATIVES EEF2K, VPS26B, VPS28 ALDH1A1 4293/4885HTT 3031/4885SMN1; SMN2 2885/4885
US-10017509-B2 Macrocylic pyrimidine derivatives EEF2K, VPS26B, VPS28 ALDH1A1 4293/4885HTT 3031/4885SMN1; SMN2 2885/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.